• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Prime Success Sends Letter to Sinovac Biotech Shareholders

    6/10/25 7:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email

    Details Why Change is Needed on Sinovac's Board in Order to Restore Company's Previous Success and Reverse Value-Destructive Path Taken Under Current Board

    Affirms Commitment to Seeing Company Reinstate Trading on the NASDAQ, Fairly Issue Dividends and Overhaul Corporate Governance

    Encourages Shareholders to Support Slate of Director Nominees Proposed by SAIF for Election at Upcoming July 8 Special Meeting

    For More Information, Visit www.SaveSinovac.com

    Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding shares, today issued a letter to shareholders in connection with the upcoming Special Meeting of Shareholders (the "Special Meeting") scheduled for July 8, 2025.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610033915/en/

    The full text of the letter can be viewed here and by visiting www.SaveSinovac.com.

    In its letter, Prime Success outlines the need for change on Sinovac's Board of Directors (the "Board") and presents key reasons to support the election of SAIF Partners IV L.P.'s ("SAIF") nominees, who are committed to taking the following value-enhancing actions:

    1. Oversee a fair, equitable, and timely distribution of cash dividends, including fully supporting the payment of the announced dividend of approximately $55 per share to all shareholders, but also actively advocating for the distribution of future dividends from the subsidiaries. Prime Success wants to ensure that the value accumulated in the Company under the management team's leadership over the years is rightfully returned to all shareholders in a timely manner.
    2. Reinstate normal trading of the Company's shares on NASDAQ and stabilize operations by resolving the uncertainty created by the current Board and taking steps to put the external auditor back on track.
    3. Overhaul governance and rebuild investor trust by adhering to corporate governance best practices, promoting greater transparency and enhancing board accountability.
    4. Lay the groundwork for sustainable long-term growth by leveraging the candidates' independence, backgrounds, and expertise to support the Company's continued development and expansion.

    Prime Success contrasts this with the current Sinovac Board members, who have:

    1. Taken actions leading to and prolonging the 2019 NASDAQ halt of trading in the Company's shares, significantly harming Sinovac's growth.
    2. Impeded the Company's ability to issue dividends over the past seven years through prolonged litigation stemming from 1Globe Capital LLC's ("1Globe") undisclosed efforts to seize board control, causing significant shareholder harm.
    3. Wasted Company resources on multiple lawsuits across various forums at the broader shareholder base's expense.
    4. Weaponized Sinovac's allocation of capital as part of their attempt to invalidate the shares of long-term investors by attempting an unjust and potentially unlawful scheme of dividend distribution.
    5. Prioritized personal interests over fiduciary obligations to all shareholders by seeking to void the Company's contractual obligations to benefit current Board members.
    6. Created significant operational uncertainty by attempting to invalidate the decisions made by the prior Board that directly led to the Company's tremendous global commercial success in the past few years, resulting in the resignation of Sinovac's external auditor.
    7. Alienated management to such a significant degree that the Sinovac management team issued an unprecedented public statement calling for a new Board election.1
    8. Appointed directors with flawed ethics through questionable and potentially unlawful procedures, resulting in disproportionate representation of investors and eroding shareholder trust.

    Prime Success shares its belief that supporting SAIF's slate is essential for the future success of Sinovac and encourages shareholders to wait for and read SAIF's proxy materials before voting for the Special Meeting on July 8, 2025.

    About Prime Success, L.P.

    Prime Success is an investment vehicle established by Advantech Capital specifically to invest in Sinovac and Sinovac Life Sciences; Advantech Capital is a private equity fund established in 2016 with a focus on innovation-driven growth opportunities in China.

    ____________________________________

    1 Press Release: SINOVAC Management Statement Regarding Auditor Resignation (April 22, 2025)

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250610033915/en/

    Media Contact

    Longacre Square Partners

    Dan Zacchei / Miller Winston

    [email protected]

    Get the next $SVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

    Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel's decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of

    1/22/26 6:00:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

    Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court's interlocutory order governing the Company's board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP ("Zhonghua"), an affiliate of the global accounting network UHY International, as the Company's independent auditor and registered public accounting firm. Update on Antigua High Court Order Further to the order issued by the Antigua High Court (the "Court") previously disclosed by the Company in a press release dated December 17, 2025, the Cour

    1/4/26 10:13:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

    Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the "Notification Letter") from Nasdaq Listing Qualifications ("Nasdaq"), stating that the Company was not in compliance with Nasdaq's Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the "Staff Determination") from Nasdaq in November 2025. The Company requested a hearing before t

    1/4/26 10:00:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    SEC Filings

    View All

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    1/30/26 3:24:16 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    1/30/26 3:23:47 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

    1/30/26 3:24:02 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Heng Ren Partners/

    In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issued Nov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment BOSTON, Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared b

    11/11/25 5:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Newly Elected Directors of Sinovac Hold the First Board Meeting

    Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the Company (the Board), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the new Directors), held its first meeting today at the Company's headquar

    7/10/25 7:23:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

    Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, shareholders should contact Dividend Information Agent D.F. King at [email protected] The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the previously declared US$55.00 per common share special cash dividend is in the process of being paid to valid shareholders who owned SINOVAC shares as of

    7/9/25 12:27:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    View All

    SINOVAC Announces Appointment of Independent Auditor

    Critical step in improving transparency and resuming trading on NASDAQ The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Audit Committee of the Board has approved the engagement of UHY LLP ("UHY") headquartered in the U.S. as its independent auditor and registered public accounting firm, effective today, October 24, 2025. UHY is a U.S. member of Urbach Hacker Young International Limited (UHY International), a UK company, and forms part of the international UHY network of legally independent accounting and consulting firms. As a matter of priority, UH

    10/24/25 10:30:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

    Special Meeting validly adjourned until the appropriate court makes a final decision on validity of the PIPE shares and will be reconvened SAIF and the Dissenting Investor Group's deceptive claims of a "continuation of the Special Meeting" and a pretend "Board" are fake and without legal basis Current Board remains the only valid board of directors of SINOVAC and will continue to govern the Company The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company") today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the "Special Meeting"): The Special Meeting was validly adjourned by SINOVAC Chairman Chian

    7/11/25 4:21:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

    Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced

    7/7/25 1:46:00 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    9/12/24 4:03:46 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

    SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    6/17/24 4:02:44 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

    SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

    3/20/24 7:33:23 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care